The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
Roger S McIntyre1,2 1Department of Psychiatry, University of Toronto, 2Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada Abstract: Although many branded and generic antidepressants are approved for the treatment of major depressive disorder (MDD) in Canada, eff...
Guardado en:
Autor principal: | McIntyre RS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d40558993d764a58a049ed3e652c0a7d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
por: Xin KZ, et al.
Publicado: (2019) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong Z, et al.
Publicado: (2017) -
The noradrenergic paradox: implications in the management of depression and anxiety
por: Montoya A, et al.
Publicado: (2016) -
Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan H, et al.
Publicado: (2019) -
Effect of Depression and Antidepressants on Sexual Dysfunction in Men with Diabetes: A National Population-Based Cohort Study
por: Chung PL, et al.
Publicado: (2020)